Related references
Note: Only part of the references are listed.High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients
Mars B. van 't Veer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Proliferation Predicts Failure-free Survival in Mantle Cell Lymphoma Patients Treated With Rituximab Plus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine
Mar Garcia et al.
CANCER (2009)
Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
Peter Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue:: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Christian H. Geisler et al.
BLOOD (2008)
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Eva Hoster et al.
BLOOD (2008)
Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue
Elena Hartmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study
Eric D. Hsi et al.
LEUKEMIA & LYMPHOMA (2008)
Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade lymphoma Study Group
Olaf Determann et al.
BLOOD (2008)
The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma
T Katzenberger et al.
BLOOD (2006)
Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL):: a clinicopathological study from the European MCL Network
M Tiemann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network
M Dreyling et al.
BLOOD (2005)
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
A Rosenwald et al.
CANCER CELL (2003)
Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma
R Räty et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2002)
Share Paper
